Attaining and Maintaining Wellness in Obsessive-compulsive Disorder
Status: | Completed |
---|---|
Conditions: | Psychiatric |
Therapuetic Areas: | Psychiatry / Psychology |
Healthy: | No |
Age Range: | 18 - 75 |
Updated: | 3/15/2019 |
Start Date: | October 2012 |
End Date: | July 2018 |
Attaining and Maintaining Wellness in OCD
The goal of this study is to understand whether patients with obsessive-compulsive disorder
(OCD) on serotonin reuptake inhibitors (SRIs) who receive a type of Cognitive-behavioral
therapy called Exposure and Ritual Prevention (EX/RP) can discontinue their medication if
they first do well with EX/RP.
(OCD) on serotonin reuptake inhibitors (SRIs) who receive a type of Cognitive-behavioral
therapy called Exposure and Ritual Prevention (EX/RP) can discontinue their medication if
they first do well with EX/RP.
This study begins with a Preparatory Phase, wherein all eligible participants receive up to
25 sessions of Exposure and Ritual Prevention (EX/RP) therapy. At the end of the Preparatory
Phase, those who have achieved wellness (mild to minimal symptoms) enter the Study Phase.
Those who do not achieve wellness will not continue in the study and are referred for
treatment elsewhere. Those who enter the Study Phase are then assigned by chance to one of
two groups. One group will continue on the SRI medication and the other group will
discontinue the SRI gradually over 4-6 weeks as it is replaced with a placebo (sugar pill).
Neither patients nor study staff will know which group a participant is in. Both groups will
continue to receive monthly sessions of EX/RP. The study will examine who has the best
response to treatment in this study, including taking blood samples for genetic testing to
see whether there are genes that can predict who will or will not benefit from EX/RP.
25 sessions of Exposure and Ritual Prevention (EX/RP) therapy. At the end of the Preparatory
Phase, those who have achieved wellness (mild to minimal symptoms) enter the Study Phase.
Those who do not achieve wellness will not continue in the study and are referred for
treatment elsewhere. Those who enter the Study Phase are then assigned by chance to one of
two groups. One group will continue on the SRI medication and the other group will
discontinue the SRI gradually over 4-6 weeks as it is replaced with a placebo (sugar pill).
Neither patients nor study staff will know which group a participant is in. Both groups will
continue to receive monthly sessions of EX/RP. The study will examine who has the best
response to treatment in this study, including taking blood samples for genetic testing to
see whether there are genes that can predict who will or will not benefit from EX/RP.
Preparatory Phase
Inclusion Criteria:
- Primary diagnosis of OCD
- Currently on a stable and adequate dose of a serotonin reuptake inhibitor (i.e.,
clomipramine, fluoxetine, fluvoxamine, sertraline, paroxetine, citalopram,
escitalopram) but still have clinically significant OCD symptoms
Exclusion Criteria:
- Comorbid Psychiatric conditions that significantly elevate the risks of study
participation (e.g. psychotic disorders, bipolar disorder, evidence of dementia or
other cognitive disorder, suicidality)
- Unstable medical conditions that need attention and would make participation in the
study unsafe (e.g., very high blood pressure)
- Patients who have already had prior adjunctive EX/RP (more than 8 sessions within 2
months) while receiving an adequate SRI trial
- Patients taking other medications besides an SRI (e.g. antipsychotics, mood
stabilizers, other antidepressants besides SRIs)
- Patients who are pregnant, sexually active and not using contraception, or nursing
Study Phase
Inclusion Criteria:
- Those who achieve mild to minimum OCD symptoms from Preparatory Phase will enter the
Study Phase
Exclusion Criteria:
- All exclusions listed above for Preparatory Phase are exclusions for Study Phase as
well
- Patients who are depressed at the end of the Preparatory phase are excluded from Study
Phase
We found this trial at
2
sites
Philadelphia, Pennsylvania 19104
Principal Investigator: Edna Foa, Ph.D.
Phone: 215-746-3327
Click here to add this to my saved trials
1051 Riverside Dr
New York, New York 10032
New York, New York 10032
646-774-5000
Principal Investigator: Helen B Simpson, MD Ph.D.
Phone: 646-774-8062
New York State Psychiatric Institute The New York State Psychiatric Institute (NYSPI), established in 1895,...
Click here to add this to my saved trials